What is the prevalence of Familial Adenomatous Polyposis?

Familial Adenomatous Polyposis (FAP) is a rare hereditary condition with an estimated prevalence ranging from 1 in 7,000 to 1 in 22,000 individuals worldwide. While often categorized as a rare disease, the true prevalence of Familial Adenomatous Polyposis may be higher due to underdiagnosis in families who are not yet aware of their genetic status.

What is the estimated prevalence and incidence of Familial Adenomatous Polyposis?

According to the NIH Genetic and Rare Diseases Information Center (GARD), the prevalence of Familial Adenomatous Polyposis is generally cited as 1 in 7,000 to 1 in 22,000. The incidence of new cases is estimated at approximately 1 in 20,000 to 30,000 live births. It is important to note that these figures are estimates; because Familial Adenomatous Polyposis symptoms may not manifest until adolescence or early adulthood, some individuals remain undiagnosed until complications arise.

Does Familial Adenomatous Polyposis affect specific groups differently?

Familial Adenomatous Polyposis affects males and females equally, as it is an autosomal dominant condition caused by mutations in the APC gene. Regarding geography and ethnicity, there is no evidence that Familial Adenomatous Polyposis is more common in any specific population or region. However, challenges in accurate data collection persist because registries for Familial Adenomatous Polyposis are not uniform across all countries, leading to potential reporting gaps.

What is the typical age of onset for Familial Adenomatous Polyposis?

The clinical presentation of Familial Adenomatous Polyposis typically occurs in two phases:

• Childhood/Adolescence: The appearance of hundreds to thousands of adenomatous polyps in the colon often begins during the teenage years.


• Early Adulthood: Without prophylactic intervention, the risk of these polyps progressing to colorectal cancer reaches nearly 100% by age 40.

How does the DiseaseMaps community reflect these statistics?

While clinical literature provides broad statistical ranges, the 147 people with Familial Adenomatous Polyposis who have joined the DiseaseMaps.org community provide a vital, real-world perspective. These community members highlight the importance of early genetic screening and ongoing surveillance, which are essential for managing the long-term health outcomes of those living with Familial Adenomatous Polyposis.

Next steps

• Consult with a clinical geneticist to discuss genetic testing and family screening protocols.


• Speak with a gastroenterologist specializing in hereditary colorectal cancer syndromes.


• Connect with the 147 members on DiseaseMaps.org to share experiences and coping strategies.

Medical disclaimer: This information is for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD) - Familial Adenomatous Polyposis


• Orphanet (ORPHA:734) - Familial Adenomatous Polyposis


• OMIM (Online Mendelian Inheritance in Man) - #175100


• The Polyposis Registry and patient advocacy resources